Youssef L Bennani
Overview
Explore the profile of Youssef L Bennani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliva M, Prota A, Rodriguez-Salarichs J, Bennani Y, Jimenez-Barbero J, Bargsten K, et al.
J Med Chem
. 2020 Jul;
63(15):8495-8501.
PMID: 32657585
Noscapine is a natural alkaloid that is used as an antitussive medicine. However, it also acts as a weak anticancer agent in certain models through a mechanism that is largely...
2.
Wang T, Bemis G, Hanzelka B, Zuccola H, Wynn M, Moody C, et al.
ACS Med Chem Lett
. 2017 Dec;
8(12):1224-1229.
PMID: 29259738
Drug resistant tuberculosis (TB) infections are on the rise and antibiotics that inhibit through a novel mechanism could be an important component of evolving TB therapy. Protein kinase A (PknA)...
3.
Farmer L, Clark M, Boyd M, Perola E, Jones S, Tsai A, et al.
ACS Med Chem Lett
. 2017 Feb;
8(2):256-260.
PMID: 28197322
In our efforts to develop novel small-molecule inhibitors for the treatment of influenza, we utilized molecular modeling and the X-ray crystal structure of the PB2 subunit of the influenza polymerase...
4.
Farmer L, Ledeboer M, Hoock T, Arnost M, Bethiel R, Bennani Y, et al.
J Med Chem
. 2015 Aug;
58(18):7195-216.
PMID: 26230873
While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential...
5.
ODowd H, Shannon D, Chandupatla K, Dixit V, Engtrakul J, Ye Z, et al.
ACS Med Chem Lett
. 2015 Jul;
6(7):822-6.
PMID: 26191374
Benzimidazole 1 is the lead compound resulting from an antibacterial program targeting dual inhibitors of bacterial DNA gyrase and topoisomerase IV. With the goal of improving key drug-like properties, namely,...
6.
Giroux S, Bilimoria D, Cadilhac C, Cottrell K, Denis F, Dietrich E, et al.
Bioorg Med Chem Lett
. 2015 Jan;
25(4):940-3.
PMID: 25597006
The discovery of non-symmetric thienoimidazole-containing HCV NS5A inhibitors is described. The inhibitors herein reported display high potencies against both genotype 1a and 1b. In this follow-up manuscript, we discuss the...
7.
Giroux S, Bilimoria D, Cadilhac C, Cottrell K, Denis F, Dietrich E, et al.
Bioorg Med Chem Lett
. 2015 Jan;
25(4):936-9.
PMID: 25595681
The discovery of C2-symmetric bis-thienoimidazoles HCV NS5A inhibitors is herein reported. Two straightforward approaches to access the requisite diyne and biphenyl linker moieties are described. This study revealed the paramount...
8.
Henderson J, Bilimoria D, Bubenik M, Cadilhac C, Cottrell K, Dietrich E, et al.
Bioorg Med Chem Lett
. 2015 Jan;
25(4):944-7.
PMID: 25577041
The treatment of HCV with highly efficacious, well-tolerated, interferon-free regimens is a compelling clinical goal. Trials employing combinations of direct-acting antivirals that include NS5A inhibitors have shown significant promise in...
9.
Henderson J, Bilimoria D, Bubenik M, Cadilhac C, Cottrell K, Denis F, et al.
Bioorg Med Chem Lett
. 2015 Jan;
25(4):948-51.
PMID: 25577039
Inhibitors of the HCV NS5A nonstructural protein are showing promising clinical potential in the treatment of hepatitis C when used in combination with other direct-acting antiviral agents. Current NS5A clinical...
10.